DATAR - trucheck
EARLY DETECTION OF CANCER
The Trucheck test is an advanced non-invasive blood test for the early detection of cancer.
The test detects circulating tumour cells (CTCs) released by malignant tumours and can identify several types of solid tumours with high accuracy.
The Trucheck test allows cancer to be detected at an early stage, improving the chances of successful treatment.
It is mainly recommended for people aged between 40 and 70, but younger individuals at increased risk of cancer can also have it.
Trucheck is particularly recommended for:
...asymptomatic individuals with a family history of cancer.
...individuals who want to include this test in their annual health check-up
...asymptomatic individuals at high risk of cancer.
No queues
Results in 10-14 days
Only a blood test is needed
Experienced specialists
About the trucheck test
Around 4.4 million new cancers are diagnosed in Europe every year, as are around 2 million cancer-related deaths.
Unfortunately, cancer is often only detected at an advanced stage, requiring more intensive and expensive treatments that have a higher risk of side effects.
Early detection of cancer, or detection at local stages, can be the key to successful treatment.
Trucheck™ is the result of several years of collaborative international research and innovation and has been developed, tested and validated in more than 40,000 individuals.
Benefits
Unlike screening tests that target one cancer at a time, Trucheck™ can detect multiple cancers that may not be detected by existing technologies with a simple blood draw. Detection at earlier stages is associated with higher treatment success and improved survival.
Trucheck™ intelli screens CTCs (circulating tumour cells) according to the molecular footprint of the tumour mass from which the CTCs originated. In other words, Trucheck™ intelli reveals diagnostically relevant information about the tissue or organ of origin of the tumour with high precision. This guides further investigations and reduces diagnostic trial and error.
Trucheck™ is an advanced comprehensive cancer detection system that offers an unparalleled combination of sensitivity and specificity for the early detection of cancer in asymptomatic individuals.
Options
The following options are available:
- Trucheck™ intelli (up to 70 types of solid tumours)
- Trucheck™ FemmeSafe (breast, ovary, uterus, cervix)
Frequently asked questions
Are there age limits for Trucheck™ analysis?
If yes, are there exceptions?
Trucheck™ is recommended for individuals aged between 40 and 70 years, as ageing is an important risk factor for cancer.
However, it may also be offered to individuals aged 35 to 40 years if any of the following risk factors apply:
1. Family history of cancer and/or known carrier status
2. Presence of risk inherited germ cell mutations
3. Obesity
4. Type 2 diabetes
5. Past infections (HPV, Hepatitis B or C viruses)
6. Documented/significant exposure to certain chemicals or carcinogens.
What are the benefits of Trucheck™ analysis?
Trucheck™ only requires a simple blood test.
Cancers that are not detected by current standard methods can be detected.
Early detection of cancer is linked to better treatment success.
What are the risks of Trucheck™ analysis?
Knowing that you are at risk or have cancer, even if it is at an early stage, can have a significant psychological impact on patients.
Patients should be aware that they may still need to have regular screening tests according to established guidelines, as Trucheck™ is not intended to replace standard cancer screening methods.
